trial summary · NCT07631325
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Unresectable Cutaneous Melanoma, sponsored by John Kirkwood. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.
Source record: https://clinicaltrials.gov/study/NCT07631325
Facts
| registry id | NCT07631325 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Unresectable Cutaneous Melanoma |
| sponsor | John Kirkwood |
| sponsor class | OTHER |
| enrollment | 28 |
| start date | 2026-11-30 |
| primary completion | 2028-07-31 |
| completion | 2030-07-31 |
| results posted | not reported |
Conditions
- Unresectable Cutaneous Melanoma
Interventions
- Axelopran
- Nivolumab
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.